Century Therapeutics financials
$1.65−1.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $109.2M | $4.2M | $791.0K | $771.0K | $855.0K | $268.0K | $148.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $109.2M | $4.2M | $791.0K | $771.0K | $855.0K | $268.0K | $148.0K |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$36.5M | -$23.7M | -$20.7M | -$36.1M | -$34.7M | $74.2M | -$37.3M | -$34.8M | -$34.8M | -$31.3M | -$43.8M | -$35.6M |
| Net income | -$34.5M | -$21.6M | -$19.2M | -$34.4M | -$32.5M | $76.6M | -$36.1M | -$31.2M | -$31.2M | -$28.1M | -$39.4M | -$32.7M |
| Net margin | — | — | — | — | — | 70.1% | −864.4% | −3947.7% | −4047.6% | −3282.1% | −14700.7% | −22108.1% |
| Diluted EPS | $-0.17 | $-0.11 | $-0.22 | $-0.40 | $-0.38 | $0.89 | $-0.42 | $-0.37 | $-0.38 | $-0.45 | $-0.66 | $-0.55 |
| EBITDA | -$22.8M | -$20.7M | -$17.1M | -$26.2M | -$31.5M | $77.4M | -$29.6M | -$31.5M | -$31.3M | -$28.1M | -$28.1M | -$32.3M |
| Operating cash flow | -$19.8M | -$25.3M | -$16.1M | -$25.6M | -$27.6M | -$34.6M | -$24.2M | -$28.3M | -$27.3M | -$30.2M | -$26.2M | -$13.6M |
| Free cash flow | -$20.5M | -$25.8M | -$16.2M | -$25.8M | -$27.9M | -$35.1M | -$24.4M | -$29.1M | -$27.6M | -$30.8M | -$27.2M | -$16.9M |
| Diluted shares | 205.8M | 193.5M | 87.4M | 86.5M | 86.2M | 86.1M | 85.5M | 84.7M | 82.1M | 62.3M | 59.9M | 59.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $49.6M | $51.0M | $61.9M | $55.5M | $56.9M | $51.9M |
| Short-term investments | $70.1M | $83.8M | $55.3M | $77.2M | $99.0M | $113.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $287.0M | $326.6M | $223.7M | $244.7M | $284.7M | $315.6M |
| Total liabilities | $54.7M | $61.8M | $64.8M | $68.4M | $74.8M | $75.2M |
| Shareholders' equity | $232.3M | $264.7M | $158.9M | $176.3M | $209.9M | $240.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology